CSF3R T618I, ASXL1 G942 fs and STAT5B N642H trimutation co‐contribute to a rare chronic neutrophilic leukaemia manifested by rapidly progressive leucocytosis, severe infections, persistent fever and deep venous thrombosis

Aki, S.Z., Suyani, E., Bildaci, Y., Cakar, M.K., Baysal, N.A. & Sucak, G.T. (2012) Prognostic role of pretransplantation serum C-reactive protein levels in patients with acute leukemia undergoing myeloablative allogeneic stem cell transplantation. Clinical Transplantation, 26, E513–E521. Artz, A.S., Wickrema, A., Dinner, S., Godley, L.A., Kocherginsky, M., Odenike, O., Rich, E.S., Stock, W., Ulaszek, J., Larson, R.A. & van Besien, K. (2008) Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 14, 1209–1216. Gratwohl, A. (2012) The EBMT risk score. Bone Marrow Transplantation, 47, 749–756. Gratwohl, A., Hermans, J., Goldman, J.M., Arcese, W., Carreras, E., Devergie, A., Frassoni, F., Gahrton, G., Kolb, H.J., Niederwieser, D., Ruutu, T., Vernant, J.P., de Witte, T. & Apperley, J. (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet, 352, 1087–1092. Pavlu, J., Kew, A.K., Taylor-Roberts, B., Auner, H.W., Marin, D., Olavarria, E., Kanfer, E.J., MacDonald, D.H., Milojkovic, D., Rahemtulla, A., Rezvani, K., Goldman, J.M., Apperley, J.F. & Szydlo, R.M. (2010) Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood, 115, 4018–4020. Sorror, M.L., Maris, M.B., Storb, R., Baron, F., Sandmaier, B.M., Maloney, D.G. & Storer, B. (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 106, 2912–2919.